Monoclonal Antibodies & Interferons: Production, Uses & Role in Infection & Cancer | A-Level Biology
Master Monoclonal Antibodies & Interferons: Production, Uses & Role in Infection & Cancer | A-Level Biology
This lesson is crafted to meet the rigorous Cambridge AS- A Level Biology (9700) followed by top-tier institutions like British International School of Tbilisi (Georgia, Europe), The British School of Brussels - BSB (Belgium), Byron College (Athens, Greece) St. Julian's School (Lisbon, Portugal) King's College, The British School of Madrid (Spain) , Harrow International School (Hong Kong / Bangkok), these resources are designed to simplify complex concepts and guarantee top grades in your board examinations.
Before diving into Monoclonal Antibodies & Interferons: Production, Uses & Role in Infection & Cancer | A-Level Biology ensure you have gone through our previous guide : Cambridge AS & A Level Biology: Immunity Master Notes (Syllabus 9700)
Table of Contents
- Introduction to Immune Proteins Monoclonal Antibodies (mAbs)
- What are Monoclonal Antibodies?
- The Hybridoma Technology (Step-by-Step Production)
- Applications of Monoclonal Antibodies in Diagnostics (Pregnancy Testing, AIDS Screening)
- Monoclonal Antibodies in Therapeutics (Targeted Cancer Therapy)
- What are Interferons (IFNs) ? How Do They Work?
- Mechanism of Viral Inhibition
- Clinical Applications (Treatment of Hepatitis and Cancer)
- Key Differences: Antibodies vs. Interferons (Comparison Table)
- AO1 Knowledge with Understanding (Direct & Recall Questions)
- AO2 Application of Knowledge (Diagram & Labeling Questions)
- AO3 Experimental Skills & Data Interpretation (Graph & Table Questions)
Introduction to Immune Proteins
Monoclonal Antibodies (mAbs)
- To fight infections, our immune system naturally produces a mixture of different antibodies—known as a polyclonal response. However, modern biotechnology allows us to produce highly specific, identical antibodies in a laboratory setting.
- Among these engineering marvels, Monoclonal Antibodies (mAbs) and Interferons are the two most crucial immune proteins. Together, they have revolutionized how we diagnose infections and treat complex diseases like cancer.
What are Monoclonal Antibodies (mAbs)?
- Monoclonal Antibodies (mAbs) are identical antibodies that are artificially produced from a single clone of a B-lymphocyte.
- Unlike natural antibodies, mAbs are Structurally Identical, Since they come from the exact same clone, every single antibody molecule is identical.
- They target the exact same epitope or binding site on a specific antigen.
The Hybridoma Technology (Step-by-Step Production)
- Mature B-lymphocytes can produce antibodies but cannot divide outside the body. Conversely, cancer cells or myeloma cells can divide indefinitely but do not produce antibodies.
- Understand the step by step the Hybridoma technology through its flow chart :
Immunization of mouse ➡️ isolation of B lymphocytes from spleen➡️ fusion of Myeloma cells ➡️ selection of suitable cells using HAT medium ➡️ Cloning and harvesting of cells.
 |
| The Hybridoma Technology (Step-by-Step Production) |
- Scientists fuse them together using Hybridoma Technology to get the best of both worlds:
- Immunization: A mouse is injected with a specific antigen to stimulate its B-lymphocytes.
- Isolation: The spleen of the mouse, containing the activated B-lymphocytes, is harvested.
- Fusion: B-lymphocytes are fused with myeloma cells (cancerous plasma cells) using Polyethylene Glycol (PEG).
- Selection: The mixture is cultured in a selective HAT medium. Only the successfully fused cells—called Hybridoma cells—survive.
- Cloning & Harvesting: The specific hybridoma cell producing the desired antibody is screened, cloned indefinitely, and the pure monoclonal antibodies are harvested.
💡Read also to understand about the Cambridge AS & A Level Biology: Immunity Master Notes (Syllabus 9700)
- Monoclonal antibodies (mAbs) are widely used in diagnostic kits because of their extreme specificity and ability to detect even microscopic amounts of a target antigen or hormone.
- Two of the most common applications required in the A-Level syllabus are Pregnancy Testing and AIDS Screening.
Pregnancy Testing Kits
- Home pregnancy test kits use monoclonal antibodies to detect the presence of a hormone called hCG (human Chorionic Gonadotropin).
- This hormone is secreted by the developing placenta shortly after implantation and is excreted in the mother's urine. The test strip contains three distinct zones:
- This zone contains mobile (free-moving) monoclonal antibodies specific to hCG.
- These antibodies are chemically bound to a colored dye/enzyme particles.
- If hCG is present in the urine, it binds to these mobile antibodies, forming an hCG-antibody complex.
Test Zone (Immobilized hCG Antibodies):
- As the urine moves up the strip by capillary action, it reaches the test zone.
- This area contains fixed (immobilized) antibodies that also bind to hCG.
- If the hCG-antibody complex is present, it gets trapped here, concentrating the colored dye and forming a visible colored line (indicating a positive result).
Control Zone (Immobilized Control Antibodies):
- This zone contains fixed antibodies that specifically bind to the mobile antibodies themselves (regardless of whether hCG is present or not).
- This traps the remaining unbound mobile antibodies, creating a second colored line.
- This proves that the test strip is working correctly and the liquid has traveled all the way up.
 |
| Pregnancy test kit Mechanism |
AIDS Screening (ELISA Test)
- To screen for HIV/AIDS, doctors look for the presence of HIV antibodies or HIV antigens in the patient's blood sample using a technique called ELISA (Enzyme-Linked Immunosorbent Assay).
- This screening test include the following steps :
 |
| Indirect ELISA diagram : A level |
- Antigen Immobilization: The surface of a testing well is coated with specific HIV antigens.
- Primary Binding: The patient's blood serum is added to the well. If the patient is HIV-positive, their blood will contain anti-HIV antibodies which will bind specifically to the immobilized antigens. The well is then washed to remove any unbound proteins.
- Secondary Binding (The Monoclonal Antibody Step): A solution containing monoclonal antibodies linked to an enzyme is added to the well. These mAbs are specifically engineered to bind to human antibodies. The well is washed again so that only the bound enzyme-linked mAbs remain.
- Color Development: A colorless substrate for the enzyme is added. If the enzyme is present (meaning the patient has HIV antibodies), the enzyme reacts with the substrate, causing a distinct color change. The intensity of the color indicates the concentration of the infection.
📖 Deep Dive into HIV/AIDS:
Want to understand how HIV attacks T-helper cells, how it is transmitted, and the global strategies used to control its spread? Read our comprehensive guide on Infectious Diseases: HIV/AIDS – Causative Agent, Transmission, and Global Control Mechanics | Cambridge AS & A-Level Biology (9700) to master this high-yield exam topic.
Monoclonal Antibodies in Therapeutics (Targeted Cancer Therapy)
- While conventional cancer treatments like chemotherapy can damage healthy dividing cells along with cancer cells, Monoclonal Antibodies (mAbs) offer a highly targeted approach.
- Since cancer cells display specific antigens on their cell membranes known as tumor-associated antigens mAbs can be custom-designed to bind directly to them.
- Scientists use two main strategies to treat cancer using mAbs:
Direct Therapy (Immune System Activation)
- In this method, unaltered monoclonal antibodies are introduced into the body to target cancer cells directly.
- Complement Activation: The mAbs bind to the tumor-associated antigens. This flags the cancer cell, signaling the body's natural immune cells (like phagocytes and T-cells) to attack and destroy it.
- Blocking Growth Signals: Some mAbs bind to the specific receptor proteins on cancer cells that receive growth signals. By blocking these receptors, the mAbs prevent the cancer cell from dividing and spreading.
Indirect Therapy (Conjugated mAbs / Magic Bullets)
- In indirect therapy, monoclonal antibodies are chemically attached (conjugated) to a therapeutic agent, acting like a "smart delivery system" or magic bullet:
- The mAb is linked to a cytotoxic drug, a toxin, or a radioactive isotope.
- When injected, the mAb travels through the body and binds only to the cancer cells displaying the specific antigen.
- The attached drug or radiation is delivered directly into the cancer cell, killing it from within while leaving the surrounding healthy tissues completely unharmed.
💡 Tip for Exam:
📝A classic example of this is Trastuzumab (Herceptin), a monoclonal antibody used to treat certain types of breast cancer by blocking growth signal receptors.
🧬 Related Revision Resource:
To fully grasp how normal cells become cancerous, what role mutations play, and how tumors develop, check out our detailed guide on Cancer: Carcinogens, Oncogenes & Tumour Development | Cambridge AS-Level Biology (9700). Mastering this foundational topic will help you understand targeted therapies much better!
What are Interferons and How Do They Work?
- Interferons (IFNs) are a group of naturally occurring signaling proteins (cytokines) that are released by host cells in response to the presence of viruses.
- Unlike antibodies, which target pathogens directly, interferons work as cellular alarms. When a cell gets infected by a virus, it secretes interferons to warn neighboring, uninfected cells.
- These neighboring cells then brace themselves by activating specific antiviral mechanisms to prevent the virus from replicating inside them.
Mechanism of Viral Inhibition (Step-by-Step)
- When a virus attacks, interferons clear the infection using the following sequence:
- Detection & Release: A host cell gets infected by a virus and detects the viral foreign nucleic acid. This triggers the cell to transcribe and translate interferon genes, releasing interferon proteins into the extracellular fluid. (The original infected cell usually dies).
- Signal Reception: The released interferons travel to neighboring uninfected cells and bind to specific receptor proteins on their cell surface membranes.
- Antiviral State Activation: This binding triggers a secondary messenger pathway inside the healthy cell, stimulating it to produce Antiviral Proteins (AVPs).
- Blocking Replication: If the virus attempts to infect these neighboring cells, the newly formed AVPs immediately block viral replication by inhibiting viral protein synthesis and degrading viral mRNA.
.webp) |
| Mechanism of Interferon Action against Viral Infection |
Clinical Applications (Treatment of Hepatitis and Cancer)
- Thanks to recombinant DNA technology, scientists can now mass-produce human interferons in laboratories to treat critical diseases:
Treatment of Hepatitis (B and C):
- Chronic Hepatitis B and C viruses attack liver cells. Synthetic alpha-interferons (alpha- IFN ) are injected into patients to boost their body’s immune response.
- This prevents the virus from replicating further and protecting liver tissues from permanent damage (cirrhosis).
Cancer Therapeutics:
- Interferons are used as a form of immunotherapy against certain cancers (such as leukemia, melanoma, and Kaposi’s sarcoma). They work by:
- Directly slowing down or stopping the rapid division (proliferation) of cancer cells.
- Enhancing the visibility of cancer cells so that the body's natural killer (NK) cells and T-lymphocytes can easily identify and destroy them.
Key Differences: Antibodies vs. Interferons (Comparison Table)
| Feature | Antibodies (Abs) | Interferons (IFNs) |
|---|---|---|
| Nature & Type | Immunoglobulins (Specific proteins). | Cytokines (Non-specific signaling proteins/glycoproteins). |
| Produced By | Plasma cells (derived from B-lymphocytes). | Virus-infected host cells. |
| Specificity | Highly specific to a particular antigen (epitope). | Non-specific; acts against a wide range of viruses. |
| Mode of Action | Targets, neutralizes, or agglutinates pathogens directly. | Acts as a cellular alarm to stimulate antiviral protein production in healthy cells. |
| Time of Action | Slow response (takes days to develop during primary infection). | Immediate and rapid response against viral attacks. |
Topic Summary
- To wrap up this unit, remember the core principles of Monoclonal Antibodies (mAbs) and Interferons.
- Production: Monoclonal Antibodies (mAbs) are produced via Hybridoma Technology by fusing short-lived, antibody-producing B-lymphocytes with immortal myeloma (cancer) cells using PEG. The successful hybrids are selected using HAT medium.
- Diagnostics: mAbs are used to detect specific antigens. In Pregnancy Kits, they track hCG hormones across the reaction, test, and control zones. In HIV Screening (Indirect ELISA), they act as enzyme-linked secondary antibodies to detect the patient’s primary anti-HIV antibodies.
- Therapeutics: mAbs act as "magic bullets" in targeted cancer therapy, either by triggering the immune system directly or delivering cytotoxic drugs exclusively to tumor-associated antigens.
- Interferons: These are non-specific cytokines released by virus-infected cells. They stimulate neighboring uninfected cells to produce Antiviral Proteins (AVPs), effectively shutting down viral translation and mRNA replication.
💡 CIE A-Level Exam Tips (How to Score Maximum Marks)
🔴 Don't Mix Up ELISA Types: If a question asks about HIV screening, always describe Indirect ELISA. Make sure to explicitly state that the well is pre-coated with the antigen, and the patient's serum antibodies bind first before the enzyme-linked mAb is added.
🔴The Crucial Washing Steps: In any ELISA explanation question, never forget to mention the washing steps after adding the primary and secondary antibodies. Examiners look specifically for this keyword; skipping it means losing marks because unbound proteins will cause false-positive results.
🔴Why Hybridoma?
A classic 2 or 3-mark question asks why B-cells are fused with cancer cells. Your answer must clearly state: Plasma B-cells produce the desired specific antibody but cannot divide outside the body, whereas myeloma cells divide indefinitely but do not produce antibodies. Fusing them creates a hybrid that does both.
🔴Interferons vs. Antibodies: Remember that interferons do not directly attack viruses. They protect healthy cells by blocking translation/replication pathways. Also, unlike highly specific antibodies, interferons provide a fast, non-specific defense against any viral mutation.
Q1. Describe the role of Polyethylene Glycol (PEG) in hybridoma technology.
Answer: Polyethylene glycol (PEG) acts as a fusogen that alters the cell membranes of the mixed cells to facilitate their fusion. It is added to a mixture of activated plasma B-cells and immortal myeloma cells to form hybridoma cells. This fusion combines the antibody-producing capability of B-cells with the indefinite division potential of cancer cells.
Q2. Explain why the washing stages are critical after each antibody addition in an ELISA test.
Answer: The washing stages are essential to completely remove any unbound antibodies or enzyme-linked conjugates left behind in the well. If these unbound components are not washed away, the added substrate will still react with the leftover enzymes, creating a false-positive color change. Therefore, washing ensures that the final visual readout accurately reflects only the specifically bound complexes.
Q3. Distinguish between the functions of the test site and the control site on a standard pregnancy test strip.
Answer: The test site contains fixed antibodies paired with a dye substrate designed to trap the hCG-antibody complex, showing a colored line only if the woman is pregnant. In contrast, the control site contains fixed antibodies that bind specifically to the excess free antibodies that passed through the test site unchanged. The appearance of a line at the control site proves that the liquid has successfully migrated across the entire strip and the test is working correctly.
Q4. State how interferons prevent the spread of a viral infection to neighboring uninfected cells.
Answer: When interferons are released by a virus-infected cell, they travel to neighboring healthy cells and bind to their surface receptors. This binding triggers a signaling cascade that stimulates the healthy cells to produce specific Antiviral Proteins (AVPs). If the virus subsequently enters these guarded cells, the AVPs immediately degrade viral mRNA and inhibit translation, effectively halting viral replication.
Q5. What is the fundamental difference between direct and indirect monoclonal antibody therapies used in targeting cancer?
Answer: Direct mAb therapy uses unaltered antibodies that bind to tumor-associated antigens to flag cancer cells for destruction by the host's immune system or block their growth signals. On the other hand, indirect mAb therapy utilizes conjugated antibodies chemically linked to a radioactive isotope or cytotoxic drug. This allows the mAb to act as a precise delivery system, releasing the lethal payload directly into the cancer cell while sparing healthy tissue.
📝AO2 Application of Knowledge (Diagram & Labeling Questions)
Qurstion : 1 Identify cells X and Y in the given diagram, and explain the biological necessity of producing cell Y to manufacture monoclonal antibodies.
Answer: Identification: Cell X represents a Myeloma cell (cancer cell), and Cell Y represents a Hybridoma cell formed by the fusion of a plasma B-cell and a myeloma cell.
Explanation: Producing cell Y is necessary because normal activated plasma B-cells can synthesize the desired highly specific antibodies but lose their ability to divide and die quickly outside the body. Fusing them with immortal myeloma cells creates a hybridoma cell that inherits both properties: the capacity for long-term, rapid division and the continuous secretion of identical monoclonal antibodies.
Question 2 : With reference to the provided diagnostic diagram, identify components P and Q, and explain what a visible color change indicates in the context of screening a patient.
Answer: Identification: Component P is the Secondary Antibody Conjugate (enzyme-linked monoclonal antibody), and Component Q is the Target Antigen (specifically the HIV antigen attached to the well).
Explanation: A visible color change indicates a positive test result, confirming that the patient's serum contains primary antibodies that successfully bound to target antigen Q. These bound primary antibodies then anchor the enzyme-linked secondary antibody P inside the well; when the substrate is added, the retained enzyme catalyzes a chemical reaction, producing a colored readout that proves the infection exists.
Question 3 : State the primary physiological responses occurring at cellular destinations A and B upon receiving the chemical signal shown in the diagram.
Answer: At Destination A (Uninfected Cell): The binding of interferons stimulates the uninfected cell to activate pathways that degrade viral mRNA and downregulate/reduce overall protein synthesis. This effectively forms an antiviral state that prevents the virus from hijacking the cell's machinery to replicate.
At Destination B (Already Infected Cell): The interferon signals the neighboring infected cell to activate internal cellular death pathways, inducing apoptosis (programmed cell death). This localized self-destruction kills the host cell early, halting the maturation and release of new viral particles before they can escape to spread the infection further.
📝 AO3 Experimental Skills & Data Interpretation
Scenario & Data Analysis: An experiment was conducted to investigate the effect of varying concentrations of a newly synthesized monoclonal antibody (mAb) on the percentage reduction of viable breast cancer cells in a laboratory culture. The experimental data is recorded in the table below:
| Concentration of Monoclonal Antibody (μg ml-1) | Percentage of Viable Cancer Cells Remaining (%) | Percentage Reduction of Viable Cancer Cells (%) |
|---|---|---|
| 0 (Control) | 100 | 0 |
| 10 | 85 | 15 |
| 20 | 55 | 45 |
| 40 | 25 | 75 |
| 80 | 10 | 90 |
| 100 | 10 | 90 |
Q1. Identify the independent variable and the dependent variable in this clinical investigation.
Answer: The independent variable is the concentration of the monoclonal antibody micro gram /ml as it is intentionally varied by the researcher. The dependent variable is the percentage reduction of viable cancer cells (%), which is measured as the biological response to the treatment.
Q2. Describe the trend shown by the data and explain the significance of the results observed between 80 micro gram /ml and 100 micro gram /ml.
Answer: The data shows a direct relationship where increasing the monoclonal antibody concentration from 0 to 80 micro gram /ml significantly decreases the viability of cancer cells, maximizing at a 90% reduction. Between 80 micro gram /ml and 100 micro gram /ml, the percentage reduction plateaus, indicating that all target tumor-associated antigens are fully saturated by the antibodies, meaning further concentration increases yield no additional therapeutic effect.
Q3. Calculate the percentage change in the percentage of viable cancer cells remaining when the mAb concentration is increased from 10 micro gram /ml to 40 micro gram Show your working.
Answer: Working :
%change = final value - initial value X 100 / initial value
= (25 - 85 ) X 100 / 85
= -70
Statement: There is a 70.6% decrease (or -70.6% change) in the percentage of viable cancer cells remaining when the concentration is raised from 10 to 40 micro gram /ml
Q4. Explain why a control setup containing 0 micro gram /ml of monoclonal antibody is necessary for this experiment.
Answer: The control setup is vital to establish a baseline for cell viability under normal culture conditions without the therapeutic intervention. It proves that the observed cell death is explicitly caused by the action of the monoclonal antibodies rather than natural cell death, environmental fluctuations, or flaws in the growth medium.
Experimental Design (Planning Question)
A student wants to plan an investigation to determine the minimum concentration of a newly discovered interferon (\beta-IFN) required to completely inhibit viral replication in cultured kidney cells. Design a laboratory experiment to carry out this investigation.
📋 Mental Map: Core Steps for Any A-Level Experimental Design
1. Independent Variable (IV): State a range of at least 5 different concentrations/values using precise dilution methods.
⬇️
2. Dependent Variable (DV): Describe a clear, quantitative method to measure the biological response accurately.
⬇️
3. Controlled Variables (CV): Identify at least 2 specific factors (e.g., temperature, pH, volumes) to keep strictly constant.
⬇️
4. Reliability (Replicates): Specify running the entire setup in triplicates to calculate a reliable mean.
⬇️
5. Risk & Safety: Outline crucial precautions (e.g., aseptic techniques, water baths) tailored to the experiment.
Answer: Varying the Independent Variable: Prepare a range of at least five different concentrations of the \beta-interferon solution (e.g., 0 (control), 10, 20, 40, 80, and 100 unit/ml using serial dilution with sterile distilled water or a matching culture medium.
Measuring the Dependent Variable: Inoculate identical, separate cultures of healthy kidney cells with a fixed, known volume and concentration of the virus suspension. After a set incubation period, measure viral replication quantitatively by performing a plaque assay to count the number of viral plaques formed, or by using a spectrophotometer to measure the optical density/turbidity of the viral protein extract.
Controlling Key Variables: Keep the incubation temperature strictly constant at 37 degree Celsius using a thermostatically controlled incubator. Additionally, ensure that the initial population density of the kidney cells, the volume of the nutrient medium, and the total incubation time (24 hours) remain identical across all setups.
Ensuring Reliability & Safety: Perform the entire procedure under aseptic conditions inside a laminar flow hood using sterilized equipment to prevent external microbial contamination. Run the experiment in triplicates (three separate setups for each interferon concentration) to calculate a reliable mean value and identify any anomalous results.
To understand the detail information about the Cambridge A-Level Biology | Allergies & Hypersensitivity: Mechanism, IgE Antibodies, and Immune Response read my next detailed guide
This module is developed by Grip the Biology for NEET Biology, IGSCE & IB Biology students. Search "Grip the Biology" on Google for more resources.
🎯 Take Your Biology Prep to the Next Level!
Struggling with complex Cambridge 9700/AP Biology data evaluation, graphs, or past papers?
Don't worry, you don't have to study alone. Book a Free 1-on-1 Live Whiteboard Demo Session with me.
We will break down tough concepts together in real-time.👇 Click the WhatsApp button below right now to claim your free slot!
🚀 Next Steps
More Biology Hub Pages !
❓ In case of any doubt, Chat Directly: 💬 Ask Your Doubt on WhatsApp
Share with the Friends 🙂
Comments
Post a Comment